504538914
`
`09/08/2017
`
`PATENT ASSIGNMENT COVER SHEET
`
`Electronic Version v1.1
`Stylesheet Version v1.2
`
`EPASID: PAT4585621
`
`
`
`SUBMISSION TYPE: NEW ASSIGNMENT
`
`
`
`
`NATURE OF CONVEYANCE:
`ASSIGNMENT
`
`CONVEYING PARTY DATA
`
`
`
`Execution Date
`
`ALLERGAN, INC.
`
`09/08/2017
`
`RECEIVING PARTY DATA
`
`SAINT REGIS MOHAWK TRIBE
`Name:
`412 STATE ROUTE 37
`Street Address:
`
`
`
`City:
`AKWESASNE
`
`State/Country:
`Postal Code:
`
`NEW YORK
`13655
`
`PROPERTY NUMBERS Total: 6
`
`
`Property Type
`Number
`Patent Number:
`
`8629111
`
`8633162
`Patent Number:
`
`
`
`
`
`
`
`
`
`
`
`Patent Number: 8642556
`
`
`
`Patent Number: 8648048
`8685930
`Patent Number:
`
`Patent Number:
`
`9248191
`
`CORRESPONDENCE DATA
`
`(714)246-4249
`Fax Number:
`Correspondencewill be sent to the e-mail addressfirst; if that is unsuccessful, it will be sent
`using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
`Phone:
`714-246-4500
`
`Email:
`Correspondent Name:
`Address Line1:
`Address Line 4:
`
`patents_ip@allergan.com
`ALLERGAN, INC.
`2525 DUPONTDRIVE, T2-7H
`IRVINE, CALIFORNIA 92612-1599
`
`
`ATTORNEY DOCKET NUMBER:
`17618
`
`LAURA L. WINE
`NAME OF SUBMITTER:
`
`
`SIGNATURE: /Laura L. Wine/
`
`DATE SIGNED:
`
`Total Attachments: 6
`
`09/08/2017
`
`504538914
`
`PATENT
`REEL: 043532 FRAME: 0422
`
`SRMT 2103 - Pg. 1
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 1
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`

`

`source=Short form-Patent Assignment - Signed#page1.tif
`source=Short form-Patent Assignment - Signed#page2.tif
`source=Short form-Patent Assignment - Signed#page3.tif
`source=Short form-Patent Assignment - Signed#page4.tif
`source=Short form-Patent Assignment - Signed#page5.tif
`
`source=Short form-Patent Assignment- Signed#page6.tif
`
`PATENT
`REEL: 043532 FRAME: 0423
`
`SRMT2103 - Pg. 2
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 2
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`

`

`EXECUTION VERSION
`
`SHORTFORMPATENTASSIGNMENT
`
`This Psteat Assignment Qhis “Assignment’) ig made ag of Septernber 8, 2017
`{euch dite, the “Effective Date"), by and between Allergan, Inc. a Delaware comoration
`CAgignar’), and Sint Regis Mohawk Tribe, 2 foderaliy-rmecognised seversign Native
`American Tribe (Assignee™),
`
`WHEREAS, Agsigner owns the patents and patent applications set forth in
`Attachment A (the “Patents};
`
`transfer, convey and deliver to
`WHEREAS, Assignor desires (© assign,
`Assignes, and Assignes wishes io acquire from Assignor, all of ite right, tide aud interest in, to
`and under the Patents; and
`
`WHEREAS,pursuant to, and upon dre terms, cbNgations and conditions off the
`Patent Assignment Agreement dated ae of September 2, 2017 (the “Long Form: Agreement"),
`by and between Aasignos and Assignen, Assiimor desires to confirm and perfectitt aselgnment,
`tranafey, conveyance and delivery to Assignees of all ofits night, Utle and interast in, ta and
`under the Patents and in, 6 and ander the inventions represenied thereby, and Assignee is
`desirous of confirming and perfecting the same.
`
`the receipt and
`NOW, THEREFORE, for good and valuaile consideration,
`anticiency of whick are hereby acknowledged, the partios herein,
`intemding by be legally
`bound, hereby agree sa follows:
`
`i, Assionment. As of the Effective Date, Assignor hereby conveys, transfers, assigns
`and delivers t Assignee, sud Assignee hereby accepts the from Assigoor, all of
`Assignor’s right, title and interest in, fo and under the Patents, together with any
`reissues, reexamination, divisions, comtinuations, contiguations«<in-part, extewsions, aad
`renawals of such Assigned Patents alreaily granted and which may be granted therean.
`The assignment sonteriplaied hersin is meant to be an absolite asgignment and not by
`way of security.
`
`3. FurtherAscurances, As may be netessury, Agsignor shall execute, acknowledge and
`deliver such other instruments, documents and agreements end shall do such other
`things as may be rcascuahly necessary, priger or advisable & carry out Hs obligations
`winder thig Agreement aad as may be reasonably necessary, proper or advisable t more
`completely effectuate, consummiete,
`record, perfect cor coofinm the transactions
`contempland hereby.
`
`3. Becardation. The Assigner hereby authorizes the Director of Patents and Trademarks
`in the United States Patent and Trademark Office & record Assignee as the asgignec
`ami owner of the Assigned Patents and to deliver fo Assiznee, amd to Assignee’s
`attorneys, Agents, sndnessors or agsigna, dll oficial domuaments and commnnicatiims ag
`may be warratted by tds Assignment, imchiding bat aot limited tc issuing any and all
`Latiers Patents of the Limtad Sites om inventions claimed in the Patents.
`
`
`iversofSovercienbrovuinity. Assignee represents that it has not and will
`& Ne Othe
`wot waive its sovereign immunity or the soversign immunity of any company,
`corporation, enterprise, authority, division, subdivision, Branch of other agency,
`
`instrumentality or other goverment component of Assignee (auch of the foregoing
`
`
`
`ii
`oy
`a hi, BATENT
`
`
`REEL 043532RAME: 0424
`
`I
`
`m
`
`SRMT 2103 - Pg. 3
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 3
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`

`

`inchadiag Assignee, 2 “Tribal Party"), in cach case, in relation fo any inter partes
`review or any other proceeding im the United Sintes Patent & Trademark CHiice or any
`adrninisirative proceeding Ghat may be filed for the purpose of invalidating or rendering
`nnenforceable any Agsipned Patents. For punsises of die Assigmrent Agreement, 20
`provision of this Assignment Aprosment should be interpretes! in comstifinte a waiver af
`Assignee’s or any other Tribal Party's sovereign immunity ag to-any inter partes review
`or similar proceedings.
`
`§.
`
`
`represeniniions, warranties, covernaots, obligations and other terme contained in the
`Long Fore Agresmeant shall not be superseded hereby, but shell remain in fall force
`and effect-to the fall extent provided therein. To the extent thal any provision of this
`Assignment ig inconsistent or conflicts with the Long Form Agreement, the provisions
`of the Long Form Agreement shall control. The parties may execute this Assignment
`in multiple counterparts, any one of which sead not contain the denature of more than
`one party, bul all such counterparts imken together shall constitute one and the same
`instrament, Any counterpart may be executed by facsimile or PDF signature and such
`faesinule or POPsignature shall be deemed an original, The terms and conditions of
`avis Azsignment shall be binding upon the parties hereto and their reapective successors
`and aszigue, This Assignment shall be governad by aed construed im accordance with
`the laws of the Siute of New York, without giving effect to the principles of conflixts
`of law thereof.
`
`[Signainres Appear On The Following Page|
`
` 3
`
`&
`é
`<
`-
`F < x RR
`REEL€64353
`
`
`
`SRMT2103 - Pg. 4
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 4
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`

`

`IN WYPNESS THEREOF, Assigaor and Assignee have caused their respective duly
`guthorised officers to exzeute this Assignment as of the Effective Date,
`
`Saint Regis Mohawk Tribe By:
`
`Name: Eric Thompson
`
`Name: A. Revert 0 Bailey
`
`Title: President
`
`Title: Trikal Chief
`
`
`
`Nuhe: Beverly Cook
`
`Tite: Tribal Chief
`
`oF ys
`
`a
`
`By: LMA,acrece
`
`Name: Michael Conners
`
`Tithe: Trikal Cluef
`
`Signature Page to Short Farm Patent Assignment Agreement, .
`«i
`
`-
`
`
`
`
`
`ved
`
`EeREEL043532 "RAME: 0426
`
`SRMT 2103 - Pg. 5
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 5
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`

`

`
` a83igk
`| 2idan2014|13/967,179
`
`
`eld713987,189
`8.642.55656
`
`
`
`
`
`LL-Feb-20l4 |
`12/987,168
`
`aiecApe2ola| POSB28
`
`7
`Abandoned
`
`
` EMG61 B18
`-“Abandoned
`EAMS61,808aSeAug2013
`
`
`
`Pending
`
`ial159
`Jan2016 Abandoned
`
`
`
`
`60503137|
`"}5-Sep-2003
`
`
`
`
`10/927,857 |
`1a-Nowss16/990,054oa
`
`
`
`_Abandoned
`
`
`aL-h“Fat3000
`
`
`”Abandoned
`
`
`annafennnnnntnwvrtnntwnennnennnnnnennafaannenanan
`i3-Nov-2004 |
`
`
`
`
`
`i _LVa79ABT
`
`al,309 v ~"Abandoned- _
`
`
`
`
`
`
`Abfechrient A ~The Patenes
`
`
`
`
`
`
`
`
`
` Abandoned
`
` LieAuge?01S|
`S101 574 Agiaoe
`
`
`Attachisient A to Shart Porm Patent dssiznment Agreement
`4a)
`
`RE oa35 2 FRAME: 0427
`
`SRMT 2103 - Pg. 6
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 6
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`

`

`
`
`SenianNo,|unFiuiseDATE ; '
`
`
`[Lu9ao
`(as78.168
`
`
`
` sri
`
`
`8,968,360
`18658,548
`
`
`
`
`Aba
`Abandoned
`
`Abandoned
`|
`
` ~14.haga) i
`
`
`rennet:
`
`2-Aug-2013
`:
`
`PAagIO3
`
`
`
`
`
`
`
`
`Abandoned
`
`Lapsed Provisional
` 16/8377
`BAugIOs |
`
`
`
` Pending ~
`
`_Lapecd Providional
`Lapsed Provisional
`
`
`
`SRMT2103- Pg. 7
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 7
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`

`

`Abandoned BFeb1016
`
`“May-20!iT porandoned
`nn
`27ROLA Pending
`
`iS-Aug-2013
`Abundoned
`lé-Apr2014
`___ Abandoned
`Pending
`Abandonad
`
`|
`
`Pending
`
`:
`
`15-erat:
`
`Attachment 4 to Short Form Patent Assignment Agrcement
`
`RECORDED: 09/08/2017
`
`
`
`ag,VENT<
`“3
`E:0429
`REEL: 043532
`FRAM
`
`SRMT 2103 - Pg. 8
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`SRMT 2103 - Pg. 8
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01131
`
`